An interventional study of No retransfusion of cardiotomy blood in Blood Loss, Surgical, sponsored by Örebro University, Sweden. Status unknown at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-05.
Sponsored by Örebro University, Sweden · Not applicable, Interventional, and Treatment
This randomised controlled trial has a non-inferiority design. The aim is to test if the blood loss (volume in mL and hemoglobin) is effected by heart and lung cardiotomy retransfusion, or not? Forty CABG (Coronary Artery By pass Grafting) patients will be allocated to either receive retransfusion (n=20) of cardiotomy blood via the heart and lung mashine, or no retransfusion (n=20).
3,000 studies on the registry are indexed under Hemorrhage; 474 are open to participants now.
This study's planned enrollment of 40 is below the median of 100 across 1,985 interventional studies indexed under Hemorrhage.
Browse Hemorrhage studies →Örebro University, Sweden is the lead sponsor of 84 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intervention group does not get cardiotomy blood retransfusion via heart-and lung machine while control does.
Procedure: No retransfusion of cardiotomy blood
No retransfusion of cardiotomy blood via heart- and lung mashine
blood loss
Hemoglobin
Time frame: During 5 days hemoglobin will be measured as the clinical rutine or as needed.
Blood loss
Blood volume in millilitre (mL)
Time frame: During 2 days or while surgical drains remains, blood volume in mL is measured.
Plan to share: No — The datasets generated and/or analysed during the current study are not publicly available due to ethical considerations of the participant integrity. Bacterial growth can be seen as sensitive data. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
No publications or documents are linked to this record.
This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Örebro University, Sweden